Plant Name: Pterocarpus santalinus
Taxonomic Information:
Plant ID: NPO1087
Plant Latin Name: Pterocarpus santalinus
Taxonomy Genus: Pterocarpus
Taxonomy Family: Fabaceae
Plant External Links:
NCBI TaxonomyDB:
1071199
Plant-of-the-World-Online:
516570-1
Used in Medicines:
Country/Region:
China; Philippines; IndiaTraditional Medicine System:
Sowa-Rigpa; Indian Folk; Unani; Siddha; Ayurveda; TCMGeographical Distribution:
Sri Lanka; India; Philippines; China
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| BCR; | |
| CA2; CA5A; CA6; CA12; CA1; CA9; CA5B; | |
| GFER; NQO2; HPGD; | |
| PTGS1; PTGS2; | |
| KDM4E; | |
| NPC1; PAX8; RAB9A; HTT; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
| Enzyme_unclassified | NQO2 | Quinone reductase 2 | P16083 | CHEMBL3959 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Protein Kinase | BCR | Bcr/Abl fusion protein | P11274 | CHEMBL2096618 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | PAX8 | Paired box protein Pax-8 | Q06710 | CHEMBL2362980 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.189E-14 | 1.589E-10 | CA1, CA12, CA2, CA5A, CA5B, CA6, CA9 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 1.237E-07 | 2.072E-04 | CYP1A1, CYP1B1, CYP3A4, NQO2, PTGS1 |
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 1.729E-07 | 2.689E-04 | CYP1A1, CYP1B1, CYP3A4, GFER, HPGD, KDM4E, NQO2, PTGS1, PTGS2 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 2.208E-07 | 3.005E-04 | CYP1A1, CYP1B1, CYP3A4, PTGS1, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0004666; prostaglandin-endoperoxide synthase activity | 1.126E-06 | 1.025E-03 | PTGS1, PTGS2 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.188E-06 | 1.035E-03 | CA1, CA12, CA2, CA5A, CA5B, CA6, CA9, NQO2 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.934E-06 | 1.583E-03 | CYP1A1, CYP1B1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 3.375E-06 | 2.371E-03 | CYP1A1, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0033993; response to lipid | 7.279E-06 | 4.803E-03 | BCR, CA2, CA9, CYP1A1, HPGD, NPC1, PTGS2 |
| BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 7.616E-06 | 4.877E-03 | CA2, CA9, CYP1A1, CYP1B1, HPGD, NPC1, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 1.124E-05 | 6.612E-03 | CYP1A1, CYP3A4 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.526E-05 | 8.307E-03 | CYP1A1, CYP1B1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 1.684E-05 | 8.732E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004064; arylesterase activity | 1.684E-05 | 8.732E-03 | CA1, CA2 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 3.744E-18 | 8.152E-14 | CA1, CA12, CA2, CA5A, CA5B, CA6, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 4.792E-15 | 5.218E-11 | CA1, CA12, CA2, CA5A, CA5B, CA6, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 8.859E-18 | 3.189E-16 | CA12, CA1, CA5B, CA2, CA5A, CA6, CA9 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.489E-06 | 2.681E-05 | CYP1A1, CYP1B1, CYP3A4, PTGS2 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 1.894E-05 | 2.273E-04 | CYP1A1, CYP1B1, PTGS2 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 2.966E-05 | 2.670E-04 | CYP1A1, CYP1B1, CYP3A4 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 5.919E-05 | 4.261E-04 | CYP1A1, CYP1B1, CYP3A4 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 7.996E-04 | 4.797E-03 | CYP1A1, CYP1B1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 1.563E-03 | 8.037E-03 | PTGS2, PTGS1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 1.912E-03 | 8.395E-03 | PTGS2, PTGS1 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 2.099E-03 | 8.395E-03 | CYP1A1, CYP3A4 |
| 09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 2.498E-03 | 8.993E-03 | CA2, CYP3A4 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2; |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1; PTGS2; |
| NA: NA | Rheumatold arthritis | NA | PTGS1; PTGS2; |
| C00-D49: Neoplasms | Cancer | C00-C96 | PTGS2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | PTGS1; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | PTGS2; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | PTGS1; PTGS2; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | PTGS2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | PTGS1; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS1; PTGS2; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2; |
| NA: NA | Miosis during ocular surgery | NA | PTGS1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PTGS2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | PTGS1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1; |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | PTGS1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | PTGS2; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PTGS2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PTGS2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PTGS2; |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1; PTGS2; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS1; PTGS2; |
| NA: NA | Joint and muscular pain | NA | PTGS2; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PTGS1; PTGS2; |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
